Trials / Completed
CompletedNCT04221217
Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
Phase 3 Long-term Study to Evaluate the Safety and Efficacy of MND-2119 in Patients With Hypertriglyceridemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Mochida Pharmaceutical Company, Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of MND-2119 at a dose of 2g/day or 4g/day for 52 weeks in patients with hypertriglyceridemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icosapent | Icosapent (MND-2119) capsules. |
Timeline
- Start date
- 2020-02-14
- Primary completion
- 2021-07-14
- Completion
- 2021-07-14
- First posted
- 2020-01-09
- Last updated
- 2021-08-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04221217. Inclusion in this directory is not an endorsement.